FDA advisors vote 8-5 in favor of GSK's Jemperli trial plan for rare rectal cancer
The FDA’s cancer advisory committee gave its backing to a set of single-arm trials proposed by GSK to gain accelerated approval …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
